M
Maria M. Mangos
Researcher at Structural Genomics Consortium
Publications - 14
Citations - 1773
Maria M. Mangos is an academic researcher from Structural Genomics Consortium. The author has contributed to research in topics: Oligonucleotide & Nucleic acid. The author has an hindex of 8, co-authored 13 publications receiving 1491 citations. Previous affiliations of Maria M. Mangos include National Research Council & McGill University.
Papers
More filters
Journal ArticleDOI
Histone recognition and large-scale structural analysis of the human bromodomain family.
Panagis Filippakopoulos,Sarah Picaud,Maria M. Mangos,T. Keates,Jean-Philippe Lambert,Dalia Barsyte-Lovejoy,I. Felletar,Rudolf Volkmer,Susanne Müller,Tony Pawson,Anne-Claude Gingras,Cheryl H. Arrowsmith,Cheryl H. Arrowsmith,Stefan Knapp,Stefan Knapp,Stefan Knapp +15 more
TL;DR: Bromodomains are protein interaction modules that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks, and a structural mechanism for the simultaneous binding and recognition of diverse diacetyl-containing peptides by BRD4 is uncovered.
Journal ArticleDOI
Transcription factor substitution during the evolution of fungal ribosome regulation.
Hervé Hogues,Hugo Lavoie,Hugo Lavoie,Adnane Sellam,Maria M. Mangos,Terry Roemer,Enrico O. Purisima,André Nantel,Malcolm Whiteway,Malcolm Whiteway +9 more
TL;DR: In all Hemiascomycetes, Rap1 substituted Tbf1 at telomeres and, in the S. cerevisiae lineage, this substitution also occurred independently at RP genes, illustrating the extreme adaptability and flexibility of transcriptional regulatory networks.
Journal ArticleDOI
Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2'F-ANA constructs containing acyclic nucleotide inserts.
Maria M. Mangos,Kyung-Lyum Min,Ekaterina Viazovkina,Annie Galarneau,Mohamed I. Elzagheid,Michael A. Parniak,Masad J. Damha +6 more
TL;DR: The butyl-modified 2'F-ANA AONs described in this work constitute the first examples of a nucleic acid species capable of eliciting high RNase H activity while possessing a highly flexible molecular architecture at predetermined sites along the AON.
Journal ArticleDOI
PRMT5 inhibition disrupts splicing and stemness in glioblastoma
Patty Sachamitr,Patty Sachamitr,Jolene Caifeng Ho,Felipe Ciamponi,Felipe Ciamponi,Wail Ba-alawi,Wail Ba-alawi,Fiona J. Coutinho,Paul Guilhamon,Paul Guilhamon,Michelle Kushida,Florence M.G. Cavalli,Lilian Lee,Naghmeh Rastegar,Victoria Vu,Victoria Vu,María Sánchez-Osuna,Jasmin Coulombe-Huntington,Evgeny Kanshin,Heather Whetstone,Mathieu Durand,Philippe Thibault,Kirsten Hart,Kirsten Hart,Maria M. Mangos,Joseph Veyhl,Wenjun Chen,Nhat Tran,Bang-Chi Duong,Ahmed Aman,Xinghui Che,Xiaoyang Lan,Owen Whitley,Olga Zaslaver,Dalia Barsyte-Lovejoy,Dalia Barsyte-Lovejoy,Laura M. Richards,Laura M. Richards,Ian Restall,Amy Caudy,Amy Caudy,Hannes L. Röst,Zahid Quyoom Bonday,Mark Bernstein,Mark Bernstein,Sunit Das,Sunit Das,Michael D. Cusimano,Julian Spears,Gary D. Bader,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,Mike Tyers,Mathieu Lupien,Mathieu Lupien,Mathieu Lupien,Benjamin Haibe-Kains,H. Artee Luchman,Samuel Weiss,Katlin B. Massirer,Katlin B. Massirer,Panagiotis Prinos,Cheryl H. Arrowsmith,Cheryl H. Arrowsmith,Cheryl H. Arrowsmith,Peter B. Dirks +66 more
TL;DR: In this paper, orthogonal-acting inhibitors of protein arginine methyltransferase 5 (PRMT5) have been shown to cause widespread disruption of splicing across the transcriptome.
Patent
Acyclic linker-containing oligonucleotides and uses thereof
TL;DR: Oligonucleotides having an internal acyclic linker residue, and the preparation and uses thereof, are described in this article, where they are used for the prevention or depletion of function of a target nucleic acid.